Navigation Links
Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Date:4/15/2009

Monday poster honored with special recognition awarded to top-rated abstracts

CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company's TransKingdom RNA interference (tkRNAi) technology will be the focus of three poster sessions featuring late-breaking research at the American Association for Cancer Research (AACR) meeting. The poster presentation scheduled for Monday afternoon, Safety and Efficacy of a tkRNAi Therapeutic Targeting Beta-Catenin (CTNNB1), received special recognition from the AACR Program Committee, which rated the abstract in the top three to four percent of those submitted. The AACR meeting will be held April 18 - 22, 2009, at the Colorado Convention Center in Denver, Colorado.

    Sunday, April 19  Characterization of a Multiple Hairpin Expression
                      Construct for TransKingdom RNA Interference (tkRNAi)
    8 am - noon
    Hall B-F          Cequent's Group Leader for Molecular Biology, Dr.
    Poster Section 27 AJ Wang will present data demonstrating that a single
    Poster board #10  tkRNAi construct can target multiple genes
    Abstract # LB-38  simultaneously and induce significant gene silencing.
                      Data presented here targets oncogenes relevant for
                      colon cancer, but this tkRNAi technology may also
                      prove useful in treatments for other cancers,
                      inflammatory diseases, and disorders

    Monday, April 20  Safety and Efficacy of a tkRNAi Therapeutic Targeting
                      Beta-Catenin (CTNNB1)
    1 - 5 pm
    Hall B-F          Cequent's Director of Development, Alison Silva, will
    Poster Section 15 present novel data showing the safety and efficacy of
    Poster board #26  orally applied tkRNAi in non-human primates against
    Abstract #LB-123  beta-catenin. These findings open the door to clinical
    Highly Rated      Phase I testing of Cequent's lead drug candidate
     Poster           CEQ508, an orally administered tkRNAi therapeutic
     Presentation     targeting the primary oncogene (beta-catenin, CTNNB1)
                      in FAP (familial adenomatous polyposis). FAP is an
                      inherited gastrointestinal disease that causes hundreds
                      of polyps to form in the colon. Today, without
                      prophylactic removal of the colon, people with FAP
                      almost inevitably develop colon cancer, and there is no
                      medical treatment available. Cequent's tkRNAi treatment
                      might provide a safe and effective tool to prevent the
                      formation of polyps and progression into cancer.

    Tuesday, April 21 Modulation of ABCB1-Mediated Multidrug Resistance (MDR)
                      by TransKingdom RNA Interference (tkRNAi)
    8 am - noon
    Hall B-F          Resistance against chemotherapy frequently complicates
    Poster Section 26 the clinical treatment of patients with cancer.
    Poster board #6   Professor Herman Lage of Charite University Hospital,
    Abstract #LB-199  Berlin, Germany, will present data describing the
                      targeting of chemotherapy resistance with tkRNAi. Here,
                      Professor Lage demonstrates the effectiveness of using
                      tkRNAi against an important multidrug resistance
                      mechanism seen in solid cancers such as gastric
                      carcinoma, ovarian cancer, and others.

About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
2. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
3. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
4. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
5. Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology
6. From eResearchTechnology to ERT
7. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
8. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
9. British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
10. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
11. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)... 2017  Zynex (OTCQB: ZYXI), an innovative medical technology company ... devices for pain management, stroke rehabilitation, cardiac monitoring and ... Company,s 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 ... Company expects to file its 2016 full year financial ... ...
(Date:3/29/2017)... March 29, 2017 According to a new market ... (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), ... published by MarketsandMarkets, the market is expected to reach USD 1,215.4 Million ... 6.5% from 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S ... serve as the official title sponsor of the Baltimore Women’s Classic, the largest all ... women will walk or run the course around the Baltimore Inner Harbor. Mercy has ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without a ... compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices has recently updated its Visio Stencils ... for free and download shapes and stencils from http://www.VisioStencils.com. , New ...
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
Breaking Medicine News(10 mins):